AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15680854 — intervention group
Group type: EXPERIMENTAL
Intervention: SMA‐CPB and MPSS (methylprednisolone, 1 g intravenous)
Number of subjects: 68
Study 15680854 — intervention group
Group type: EXPERIMENTAL
Intervention: MPSS
Number of subjects: 68
Study 11487766 — intervention group
Group type: EXPERIMENTAL
Intervention: Juice with high fructose/glucose ratios and sorbitol
Number of subjects: 60
Study 9580856 — intervention group
Group type: EXPERIMENTAL
Intervention: 185 MBq iodine-131 diagnostic imaging (G1)
Number of subjects: 51
Study 9580856 — intervention group
Group type: COMPARATOR
Intervention: Iodine-123 administration only (G0)
Number of subjects: 51
Study 8282352 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra‐arterial blood pressure after 30 minutes of supine rest
Number of subjects: 69
Study 8282352 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial plasma epinephrine after 30 minutes of supine rest
Number of subjects: 69
Study 8282352 — intervention group
Group type: COMPARATOR
Intervention: Blood pressure at screening and during mental stress and cold pressor tests
Number of subjects: 69
Study 3177083 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 15
Study 3177083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30682632 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Dialogue intervention
Number of subjects: 503
Study 30682632 — intervention group
Group type: COMPARATOR
Intervention: Usual psychiatric treatment (control group)
Number of subjects: 503
Study 28670847 — intervention group
Group type: EXPERIMENTAL
Intervention: GRS based on 17 SNPs
Number of subjects: 3239
Study 28670847 — intervention group
Group type: EXPERIMENTAL
Intervention: GRS based on 34 SNPs
Number of subjects: 3239
Study 28670847 — intervention group
Group type: EXPERIMENTAL
Intervention: GRS based on 51 SNPs
Number of subjects: 3239
Study 28670847 — intervention group
Group type: EXPERIMENTAL
Intervention: GRS based on 68 SNPs
Number of subjects: 3239
Study 28670847 — intervention group
Group type: COMPARATOR
Intervention: Negative family history
Number of subjects: 3239
Study 28670847 — intervention group
Group type: COMPARATOR
Intervention: Positive family history
Number of subjects: 3239
Study 25960375 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI + Optimal Medical Therapy (OMT)
Number of subjects: 2287
Study 25960375 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI + OMT
Number of subjects: 2287
Study 25960375 — intervention group
Group type: COMPARATOR
Intervention: OMT alone
Number of subjects: 2287
Study 24094693 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-titration group (150mg/day every 2 days)
Number of subjects: 73
Study 24094693 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-titration group (150mg/day every 4 days)
Number of subjects: 73
Study 24094693 — intervention group
Group type: COMPARATOR
Intervention: Slow-titration group (150mg/day every 7 days)
Number of subjects: 73
Study 24094693 — intervention group
Group type: COMPARATOR
Intervention: Fast-titration group vs Slow-titration group
Number of subjects: 73
Study 24094693 — intervention group
Group type: COMPARATOR
Intervention: Fast-titration group vs Slow-titration group (stratified analysis)
Number of subjects: 73
Study 24094693 — intervention group
Group type: COMPARATOR
Intervention: Medium-titration group vs Slow-titration group (stratified analysis)
Number of subjects: 73
Study 21466609 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg)
Number of subjects: 139
Study 21466609 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (960 mg)
Number of subjects: 139
Study 21466609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 19001472 — intervention group
Group type: EXPERIMENTAL
Intervention: Culotte stenting with drug-eluting stents (Cypher, Endeavor, polymer-free rapamycin-eluting, Taxus)
Number of subjects: 132
Study 19001472 — intervention group
Group type: EXPERIMENTAL
Intervention: Culotte stenting with drug-eluting stents
Number of subjects: 132
Study 16404596 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐(11)C‐acetate (ACE)
Number of subjects: 26
Study 16404596 — intervention group
Group type: COMPARATOR
Intervention: 2‐(18)F‐fluoro‐2‐deoxy‐D‐glucose (FDG)
Number of subjects: 26
Study 16404596 — intervention group
Group type: COMPARATOR
Intervention: FDG T/C ratio
Number of subjects: 26
Study 16404596 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE T/C ratio
Number of subjects: 26
Study 16404596 — intervention group
Group type: COMPARATOR
Intervention: FDG
Number of subjects: 26
Study 16404596 — intervention group
Group type: COMPARATOR
Intervention: T/C ratios and SUVs of FDG uptake
Number of subjects: 26
Study 16404596 — intervention group
Group type: EXPERIMENTAL
Intervention: T/C ratios and SUVs of ACE uptake
Number of subjects: 26
Study 12622302 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term counselling in general practice
Number of subjects: 145
Study 12622302 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine GP treatment + Short-term counselling
Number of subjects: 145
Study 12622302 — intervention group
Group type: COMPARATOR
Intervention: Routine GP treatment
Number of subjects: 145
Study 10861652 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg once daily for 12 weeks
Number of subjects: 429
Study 10861652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429
Study 10861652 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine treatment continued for 2 years
Number of subjects: 429
Study 9144683 — intervention group
Group type: COMPARATOR
Intervention: cisplatin/etoposide
Number of subjects: 0
Study 9144683 — intervention group
Group type: EXPERIMENTAL
Intervention: paclitaxel/cisplatin/G-CSF
Number of subjects: 0
Study 9144683 — intervention group
Group type: EXPERIMENTAL
Intervention: paclitaxel/cisplatin
Number of subjects: 0
Study 9144683 — intervention group
Group type: EXPERIMENTAL
Intervention: paclitaxel regimens
Number of subjects: 0
Study 7525394 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 69
Study 3131406 — intervention group
Group type: EXPERIMENTAL
Intervention: cromolyn sodium
Number of subjects: 120
Study 3131406 — intervention group
Group type: EXPERIMENTAL
Intervention: flunisolide
Number of subjects: 120
Study 3131406 — intervention group
Group type: EXPERIMENTAL
Intervention: beclomethasone
Number of subjects: 120
Study 3131406 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 120
Study 3131406 — intervention group
Group type: EXPERIMENTAL
Intervention: glucocorticoids (flunisolide and beclomethasone)
Number of subjects: 120
Study 3131406 — intervention group
Group type: EXPERIMENTAL
Intervention: topical nasal treatment
Number of subjects: 120
Study 31309730 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 0
Study 31309730 — intervention group
Group type: COMPARATOR
Intervention: Angioplasty
Number of subjects: 0
Study 27140841 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-fluid (CF) ingestion
Number of subjects: 7
Study 27140841 — intervention group
Group type: COMPARATOR
Intervention: Ice-slurry (IS) ingestion
Number of subjects: 7
Study 27802427 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (7 mg of transdermal nicotine)
Number of subjects: 30
Study 27802427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 24949547 — intervention group
Group type: EXPERIMENTAL
Intervention: Pork group (PG)
Number of subjects: 58
Study 24949547 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplement group (SG)
Number of subjects: 58
Study 24949547 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 58
Study 22610268 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine 10-30 mg/day
Number of subjects: 140
Study 22610268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 19288569 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline plus taxane chemotherapy
Number of subjects: 5486
Study 19288569 — intervention group
Group type: COMPARATOR
Intervention: Anthracyclines without taxanes
Number of subjects: 5486
Study 19288569 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 5486
Study 19288569 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors
Number of subjects: 5486
Study 19288569 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy
Number of subjects: 5486
Study 17308851 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic dilatation
Number of subjects: 51
Study 17308851 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cardiomyotomy
Number of subjects: 51
Study 15362959 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide acetate (Sandostatin LAR 10‐30 mg every 4 weeks i.m.)
Number of subjects: 14
Study 15362959 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 14
Study 12077205 — intervention group
Group type: EXPERIMENTAL
Intervention: mu-opioid system activation in response to sustained pain
Number of subjects: 28
Study 9799818 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 0
Study 7621370 — intervention group
Group type: EXPERIMENTAL
Intervention: Loaded trials with linear position feedback to a torque motor
Number of subjects: 10
Study 7621370 — intervention group
Group type: COMPARATOR
Intervention: Nonloaded trials
Number of subjects: 10
Study 7621370 — intervention group
Group type: EXPERIMENTAL
Intervention: Loaded movements in the deafferented subject
Number of subjects: 10
Study 7621370 — intervention group
Group type: EXPERIMENTAL
Intervention: Movements with load in the absence of vision
Number of subjects: 10
Study 2495053 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion nurse and general practitioner
Number of subjects: 3206
Study 2495053 — intervention group
Group type: COMPARATOR
Intervention: General practitioner alone
Number of subjects: 3206
Study 327987 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (70 to 80 mg daily maximum, titrated)
Number of subjects: 106
Study 327987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 327987 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 106
Study 6158436 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-15 c/sec EEG feedback training (subgroup I)
Number of subjects: 8
Study 6158436 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-23 c/sec EEG feedback training (subgroup II)
Number of subjects: 8
Study 6158436 — intervention group
Group type: COMPARATOR
Intervention: 6-9 c/sec EEG feedback training (control period B)
Number of subjects: 8
Study 31793473 — intervention group
Group type: COMPARATOR
Intervention: Universal adhesive application with no treatment (control)
Number of subjects: 4
Study 31793473 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal adhesive application with acid etching (37% phosphoric acid)
Number of subjects: 4
Study 31793473 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal adhesive application with Al2O3 sandblasting
Number of subjects: 4
Study 31793473 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal adhesive application with CoJet sandblasting
Number of subjects: 4
Study 31793473 — intervention group
Group type: EXPERIMENTAL
Intervention: No universal adhesive application with acid etching
Number of subjects: 4
Study 31793473 — intervention group
Group type: EXPERIMENTAL
Intervention: No universal adhesive application with Al2O3 sandblasting
Number of subjects: 4
Study 31793473 — intervention group
Group type: EXPERIMENTAL
Intervention: No universal adhesive application with CoJet sandblasting
Number of subjects: 4
Study 28653433 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading of four interforaminal implants
Number of subjects: 20
Study 28653433 — intervention group
Group type: COMPARATOR
Intervention: Conventional loading of four interforaminal implants
Number of subjects: 20
Study 26487284 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation
Number of subjects: 70
Study 26487284 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational program
Number of subjects: 70
Study 23395559 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic capsules containing Lactobacillus rhamnosus GR‐1 and Lactobacillus reuteri RC‐14
Number of subjects: 544
Study 23395559 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 544
Study 23395559 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic capsules
Number of subjects: 544
Study 21162644 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 0
Study 21162644 — intervention group
Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 0
Study 19453031 — intervention group
Group type: EXPERIMENTAL
Intervention: On-demand therapy with omeprazole 20 mg (Group A1)
Number of subjects: 216
Study 19453031 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous therapy with omeprazole 10 mg daily (Group A2)
Number of subjects: 216
Study 19453031 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily (Group B)
Number of subjects: 216
Study 19453031 — intervention group
Group type: COMPARATOR
Intervention: Health-related quality of life evaluation
Number of subjects: 216
Study 18067032 — intervention group
Group type: EXPERIMENTAL
Intervention: Fagerström Test for Nicotine Dependence (FTND)
Number of subjects: 0
Study 18067032 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to first cigarette in the morning
Number of subjects: 0
Study 15060418 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo) infusion
Number of subjects: 6
Study 15060418 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg/min t‐PA infusion
Number of subjects: 6
Study 15060418 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 microg/min t‐PA infusion
Number of subjects: 6
Study 12461199 — intervention group
Group type: EXPERIMENTAL
Intervention: Various psychosocial interventions
Number of subjects: 34
Study 12461199 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial treatments
Number of subjects: 34
Study 10443520 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 62
Study 10443520 — intervention group
Group type: COMPARATOR
Intervention: CyA
Number of subjects: 62
Study 8778009 — intervention group
Group type: COMPARATOR
Intervention: Progesterone concentration in peritoneal fluid
Number of subjects: 100
Study 2194715 — intervention group
Group type: EXPERIMENTAL
Intervention: terbinafine (125 mg b.i.d.)
Number of subjects: 92
Study 2194715 — intervention group
Group type: COMPARATOR
Intervention: griseofulvin (500 mg b.i.d.)
Number of subjects: 92
Study 2194715 — intervention group
Group type: EXPERIMENTAL
Intervention: terbinafine
Number of subjects: 92
Study 2194715 — intervention group
Group type: COMPARATOR
Intervention: griseofulvin
Number of subjects: 92
Study 353623 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (750 mg per day)
Number of subjects: 78
Study 353623 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (1,000 mg per day)
Number of subjects: 78
Study 353623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 31875616 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacrubitril/Valsartan
Number of subjects: 120
Study 31875616 — intervention group
Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 120
Study 31145699 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein feeding rich in glutamate
Number of subjects: 9
Study 31145699 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with glutamate, glutamine, and leucine
Number of subjects: 9
Study 31145699 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamate, glutamine, and leucine
Number of subjects: 9
Study 28040660 — intervention group
Group type: COMPARATOR
Intervention: Standard chemoradiotherapy (SFX) with cisplatin (100 mg/m2 IV × 3)
Number of subjects: 320
Study 28040660 — intervention group
Group type: EXPERIMENTAL
Intervention: Altered fractionation radiotherapy (AFX) with panitumumab (PMab; 9 mg/kg IV × 3)
Number of subjects: 320
Study 28040660 — intervention group
Group type: COMPARATOR
Intervention: Standard chemoradiotherapy (SFX)
Number of subjects: 320
Study 28040660 — intervention group
Group type: EXPERIMENTAL
Intervention: Altered fractionation radiotherapy (AFX) with panitumumab (PMab)
Number of subjects: 320
Study 26237830 — intervention group
Group type: COMPARATOR
Intervention: Anti-rheumatic drugs (ARDs) including oral celecoxib, methotrexate, and esomeprazole
Number of subjects: 180
Study 26237830 — intervention group
Group type: COMPARATOR
Intervention: Ginger-partitioned acupoint stimulation at zusanli (ST 36)
Number of subjects: 180
Study 26237830 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with oral sanhuangwuji powder, ginger-partitioned acupoint stimulation at zusanli (ST 36), and ARDs
Number of subjects: 180
Study 23774436 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 400 mg daily doses
Number of subjects: 169
Study 21672197 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific training to record adverse effects with subsequent feedback after instruction on the process.
Number of subjects: 54
Study 21672197 — intervention group
Group type: COMPARATOR
Intervention: No action taken (Control group).
Number of subjects: 54
Study 19665415 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 457
Study 19665415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 457
Study 16942472 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic treatment plus progressive muscular relaxation (PMR) exercises
Number of subjects: 29
Study 16942472 — intervention group
Group type: COMPARATOR
Intervention: Progressive muscular relaxation (PMR) exercises only
Number of subjects: 29
Study 14964492 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap surgery and laser treatment using an energy level of 0.8 W
Number of subjects: 12
Study 14964492 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap surgery and laser treatment using an energy level of 0.5 W
Number of subjects: 12
Study 14964492 — intervention group
Group type: COMPARATOR
Intervention: Flap surgery only (control)
Number of subjects: 12
Study 12237921 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (CPT-11) 100 mg/m² over 90 minutes, Paclitaxel 175 mg/m² over 3 hours, Carboplatin AUC 5 over 30 minutes, administered on the first day of each 21-day cycle.
Number of subjects: 40
Study 12237921 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (CPT-11), Paclitaxel, and Carboplatin combination therapy.
Number of subjects: 40
Study 9797181 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 121
Study 9797181 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 121
Study 9797181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 7639224 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 U of recombinant IFN-alpha 2b three times weekly for 24 weeks
Number of subjects: 91
Study 7639224 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 U of recombinant IFN-alpha 2b three times weekly for 24 weeks
Number of subjects: 91
Study 7639224 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 U of recombinant IFN-alpha 2b three times weekly for 24 weeks
Number of subjects: 91
Study 2562137 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg/day in addition to previous therapy with digitalis and diuretics
Number of subjects: 38
Study 2562137 — intervention group
Group type: COMPARATOR
Intervention: Continuation of previous therapy (Control)
Number of subjects: 38
Study 2562137 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg/day
Number of subjects: 38
Study 2562137 — intervention group
Group type: COMPARATOR
Intervention: Comparison of changes between groups
Number of subjects: 38
Study 362528 — intervention group
Group type: EXPERIMENTAL
Intervention: J5 antiserum
Number of subjects: 136
Study 362528 — intervention group
Group type: COMPARATOR
Intervention: Nonimmune control human serum
Number of subjects: 136
Study 29985265 — intervention group
Group type: EXPERIMENTAL
Intervention: ARV drugs detected in HIV-infected young women
Number of subjects: 2526
Study 29985265 — intervention group
Group type: COMPARATOR
Intervention: ARV drugs detected in HIV-uninfected young women
Number of subjects: 2526
Study 29985265 — intervention group
Group type: EXPERIMENTAL
Intervention: ARV drugs detected in seroconverters
Number of subjects: 2526
Study 29985265 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV drug resistance in young women with genotyping results
Number of subjects: 2526
Study 29985265 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV drug resistance in seroconverters with genotyping results
Number of subjects: 2526
Study 25944685 — intervention group
Group type: EXPERIMENTAL
Intervention: QTinno (fully automated, 5 replicates)
Number of subjects: 24
Study 25944685 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartSignals (computer-assisted manual, 3 replicates)
Number of subjects: 24
Study 25944685 — intervention group
Group type: COMPARATOR
Intervention: VERITAS (automated commercial algorithm)
Number of subjects: 24
Study 25944685 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartSignals
Number of subjects: 24
Study 25944685 — intervention group
Group type: EXPERIMENTAL
Intervention: QTinno
Number of subjects: 24
Study 25139110 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Maxillary Expansion (RME)
Number of subjects: 42
Study 25139110 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed Maxillary Expansion (MME)
Number of subjects: 42
Study 22618923 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 723
Study 22618923 — intervention group
Group type: COMPARATOR
Intervention: Control group (no active intervention)
Number of subjects: 723
Study 19825505 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with dutasteride (0.5 mg) and tamsulosin (0.4 mg)
Number of subjects: 4844
Study 19825505 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin monotherapy
Number of subjects: 4844
Study 19825505 — intervention group
Group type: COMPARATOR
Intervention: Dutasteride monotherapy
Number of subjects: 4844
Study 17588698 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate drain site radiotherapy 21Gy in three fractions (XRT arm)
Number of subjects: 61
Study 17588698 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 61